Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28399535 | 0.91 | USP2 (0.39) | HRH3ALDH1A1KDM4ETSHRUSP2 | |
| SCHEMBL5721027 | 0.89 | HRH3 (0.39) | HRH3ALDH1A1KDM4ETSHRUSP2 | |
| SCHEMBL20853432 | 0.81 | SIGMAR1 (0.33) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL5466976 | 0.80 | CHRNB2 (0.41) | HRH3ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5233749 | 0.80 | CHRNB2 (0.41) | HRH3ALDH1A1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5186716 | 0.78 | ALDH1A1 (0.38) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4042388 | 0.76 | HRH3 (0.42) | HRH3ALDH1A1KDM4ETSHRUSP2 | |
| SCHEMBL28988542 | 0.72 | — | — | |
| SCHEMBL2031634 | 0.71 | CXCR4 (0.36) | HRH3KDM4ECHRNB2CHRNB4CHRNA3 | |
| SCHEMBL28465611 | 0.70 | HRH3 (0.33) | HRH3CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ASTRAZENECA UK LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043010-A1 | Quinazoline derivatives | ERBB2, ABL1, EGFR | HRH3 1612/4885ALDH1A1 2808/4885KDM4E 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.